about
Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosisCharacterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage PolarizationRespective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinomaHormone replacement therapy after prophylactic adnexectomy.Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patientsThe molecular subtype classification is a determinant of sentinel node positivity in early breast carcinomaExternal validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement.Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification.Benign breast diseases.Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma.Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity.Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewLarge field, high resolution full-field optical coherence tomography: a pre-clinical study of human breast tissue and cancer assessmentTumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment.Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers.ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics.A new model of patient tumor-derived breast cancer xenografts for preclinical assays.Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors.Breast cancer survivors' perceived medical communication competence and satisfaction with care at the end of treatment.
P50
Q24806218-F67F3681-F7DB-4FEC-9661-98030F86D820Q27340316-FF649B66-70AA-46CC-A08E-81AA58A2FDF1Q28552410-0EB9BA87-DC0A-4573-AC8E-DAB360547B30Q28730529-B56B960F-C709-41ED-A540-0E216FFDB750Q33721579-AA077415-DE5F-46D5-AE72-0C3BE1F4E6CDQ33919243-739049C7-F45A-4E9E-8304-EBE9081F4D0DQ33927159-4904FA09-E80C-4E33-91E2-FCBF2AF3DB59Q34075697-12D6FD54-AA35-4E62-9E6E-345F54B93CF1Q34443092-41A74F32-DB5D-45F6-BB91-32036B57A29AQ34555984-1DBC67B3-3BF0-425B-A2D9-3992810DEBA7Q34633934-294B8621-E3FE-42BF-8201-0D520EB6A6DAQ35794363-B27555E5-8283-4D49-8BDE-2ABF37736103Q35904441-E1D21657-72CF-49BA-96F6-0406CDD1C9CFQ35923944-63CF6566-4EBA-4F14-9743-D9B2D191F523Q37360208-BCD7CF24-3CE7-4151-BBD8-17735D8BD958Q37662402-29B2AE83-204E-4167-872E-5668BC598D68Q37669469-ADB83F55-6022-4CDE-82BF-FD6301FE10DEQ39196943-A08DD1E2-5EA4-4A0C-96C2-9C82FFB666F3Q40112517-98910214-D374-4E09-8298-D14323DCA26EQ40375567-4F647FF6-3A05-4DD2-88E7-D716A1B33EE3Q40938010-B5C6F111-6F2F-42BB-9D2E-01DA445A7365
P50
description
onderzoeker
@nl
name
Brigitte Sigal-Zafrani
@ast
Brigitte Sigal-Zafrani
@en
Brigitte Sigal-Zafrani
@es
Brigitte Sigal-Zafrani
@sl
type
label
Brigitte Sigal-Zafrani
@ast
Brigitte Sigal-Zafrani
@en
Brigitte Sigal-Zafrani
@es
Brigitte Sigal-Zafrani
@sl
prefLabel
Brigitte Sigal-Zafrani
@ast
Brigitte Sigal-Zafrani
@en
Brigitte Sigal-Zafrani
@es
Brigitte Sigal-Zafrani
@sl